Tosoh Bioscience, part of Tosoh Corporation, is a supplier of chromatographic solutions and sophisticated diagnostic systems. Bringing quality products and services from complete in-house bioseparation and diagnostic portfolios, Tosoh Bioscience comprises two business units: Tosoh Bioscience - Separations & Purification and Tosoh Bioscience - Diagnostics.
Tosoh Bioscience - Separations & Purification business unit is a global leader in liquid chromatography focusing on bioseparations. A team of chromatography experts enables the biopharmaceutical industry to provide safe and efficient therapies against life-threatening diseases. The analytical portfolio encompasses GPC/SEC instruments, columns and detectors, and a broad range of (U)HPLC columns. Dedicated instruments, pre-packed columns, and media for purification of biomolecules from lab to production scale complete the product range.
Tosoh Bioscience - Diagnostics business unit offers high-performance automated immunoassay, HbA1c HPLC, and molecular analyzers, ranging from benchtop to high-productivity floor-standing ones. The analyzers are accompanied by a wide range of biomarkers and test-cup reagents as well as complete customer support service, providing quality solutions to laboratories, clinics, and hospitals’ needs. Although immunoassay assays come in many shapes and forms, what sets us apart from our competition is our unique 1 cup = 1 test principle which improves precision, avoids cross reactions, and guarantees long shelf life. Being one of the HPLC leaders in HbA1c monitoring and hemoglobinopathies screening, we assist our customers in their efforts to respond to the ever-growing clinical demand for fast and accurate diagnosis, by providing precise test results and reliable analytical performance based on more than forty years of experience. Additionally, we also offer open laboratory automation hardware and middleware.
Tosoh Corporation comprises over 100 companies and more than 14,000 employees worldwide. It generated net sales of ¥1,064,376 billion consolidated financial results for the fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023).